Needham reiterated a Hold rating for ResMed (NYSE:RMD), highlighting the company's second quarter fiscal year 2025 performance. ResMed reported revenue and earnings per share (EPS) that surpassed ...
The digital health unicorn sells its chronic condition management and musculoskeletal programs to employers and health plans ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
He has covered insurance for a decade, including auto, home, life and health. Before cove... Ashlee is an insurance editor, journalist and business professional with an MBA and more than 17 years ...
Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback